Intermezzo

Intermezzo is a brand name of zolpidem, approved by the FDA in the following formulation(s):

INTERMEZZO (zolpidem tartrate - tablet; sublingual)

• 
  Manufacturer: PURDUE PHARMA
  
  Approval date: November 23, 2011
  
  Strength(s): 1.75MG, 3.5MG ^[RLD]

Has a generic version of Intermezzo been approved?

No. There is currently no therapeutically equivalent version of Intermezzo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Intermezzo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
  Patent 7,658,945
  Issued: February 9, 2010
  Inventor(s): Singh; Nikhilesh N.
  Assignee(s): Transcept Pharmaceuticals, Inc.
  The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.
  
  Patent expiration dates:
  
  
  • April 15, 2027
    
    ✓ 
    Patent use: METHOD FOR TREATING INSOMNIA
    ✓ 
    Drug product
  
  



• 
  Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
  Patent 7,682,628
  Issued: March 23, 2010
  Inventor(s): Singh; Nikhilesh N.
  Assignee(s): Transcept Pharmaceuticals, Inc.
  The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.
  
  Patent expiration dates:
  
  
  • February 16, 2025
    
    ✓ 
    Patent use: METHOD FOR TREATING INSOMNIA
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 23, 2014 - NEW PRODUCT
  
  

See also...

• Intermezzo Consumer Information (Drugs.com)
• Intermezzo Consumer Information (Cerner Multum)
• Zolpidem Consumer Information (Drugs.com)
• Zolpidem Consumer Information (Wolters Kluwer)
• Zolpidem Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Zolpidem Oral Spray Consumer Information (Wolters Kluwer)
• Zolpidem Consumer Information (Cerner Multum)
• Zolpidem Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Zolpidem Tartrate AHFS DI Monographs (ASHP)